Cinnarizine is trans-1 cinnamyl-4 diphenymethyl-piperazine. Its molecular formula is C26H28N2 with a molecular weight of 368.53. Cinnarizine has a melting point of 118-120°C.
Antivertigo.
Cinnarizine is a selective calcium-entry blocker, belonging to group IV of calcium antagonists. It inhibits contractions of vascular smooth muscle cells by blocking calcium channels. In addition, it decreases the contractile activity of vasoactive substances eg, norepinephrine and serotonin, resulting to a remarkable improvement of cerebral blood flow.
Cinnarizine further improves deficient microcirculation by increasing erythrocyte deformity and decreasing blood viscosity. Cellular resistance to hypoxia is increased. Cinnarizine inhibits stimulation of the vestibular system, which results in suppression of nystagmus and other autonomic disturbances. Acute episodes of vertigo can be prevented or reduced.
Symptomatic treatment of nausea and vertigo caused by Meniere's disease and other labyrinth disorders and for the prevention and treatment of motion sickness. Management of various peripheral and cerebral vascular disorders.
1-3 tablets 3 times a day.
General: In patients suspected of intracranial hemorrhage, administration of Vertisin should be initiated from 10 days to 2 weeks after the attack where hemostasis has been estimated to be established.
Use in pregnancy: In animal studies (rats and mice), the incidence of cleft palate has been reported. Use of cinnarizine should be avoided in pregnant women or women of childbearing potential.
Use in pregnancy: In animal studies (rats and mice), the incidence of cleft palate has been reported. Use of cinnarizine should be avoided in pregnant women or women of childbearing potential.
Gastrointestinal: Occasionally, symptoms including nausea, anorexia and diarrhea have occurred.
Nervous System: Occasionally, symptoms including headache, dizziness, somnolence and fatigue have occurred.
Hypersensitivity: Occasionally, hypersensitivity symptoms including eruption and erythema on the skin or mucous membrane have occurred. When these symptoms have occurred, Vertisin should be discontinued immediately.
Store at a temperature not exceeding 30°C.
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Vertisin tab 25 mg
100's (P1,800/pack)
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
